After a strict lockdown impacting sales, India has returned to the growth path again, Anglo-Dutch FMCG major Unilever has said. The return of growth of India business, along with Brazil and continued recovery in China, helped the company's emerging markets clock a growth of 5.3 per cent in the September 2020 quarter.
Food regulator has closed more than 15 files.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
However, foreign investors have completely shunned the infrastructure sector.
GSKAP takes care of all non-nutrition products whereas GSK Consumer Healthcare is a listed entity which deals only in nutritional products.
The sensitivity segment has quadrupled in the past two years, due to the aggressive marketing effort of both GSK and Colgate.
The Nutribic biscuit, first launched in August, found itself in the eye of a storm, owing to copyright and trademark infringement issues.
According to medical practitioners, the treatment is especially useful in controlling disease among those who have not received the vaccine or got only one shot and also the high-risk contacts of a patient.
It takes 6 to 8 months after the approval for a product to hit stores.
Given the strong prospects in the business, analysts expect the company to clock healthy growth of 15-20 per cent, going ahead.
In a special series, we will put YOU to the test everyday!
This has been a season for corporate scandal.
The 'in-principle' settlement of $3 billion is covered by existing provisions. GSK expects to make payments under a final agreement next year.
Big pharma companies, however, said while it was true that formulation players would not rush to buy raw material, they could not afford losing customers.
At Trump's request, India had last month allowed the export of 50 million hydroxychloroquine tablets to treat COVID-19 patients in America, the country worst hit by the pandemic.
Pharma companies gear up for the 'new normal' as they train and align their sales forces for a paradigm shift. GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family.
The doping laboratory that will process more than 6,000 samples at this year's London Olympics has been given the seal of approval by the World Anti-Doping Agency (WADA).
Most companies see the next few quarters as a period of uncertainty and are trying to shift costs from fixed to variable.
Already having a deal with GlaxoSmithKline for marketing its products in various emerging markets, Dr Reddy's Laboratories had this week inked an agreement to buy the latter's oral penicillin manufacturing facility at Tennessee in the United States.
Dr Reddy's Laboratories on Wednesday said it has acquired GlaxoSmithKline's US penicillin manufacturing facility and the rights to the Augmentin and Amoxil brands in the United States for an undisclosed sum.
Other Health Food Drinks brands of GSK -- Boost, Maltova and Viva -- would come to HUL's portfolio by virtue of the merger, making it a leading player in the segment.
The studies, independently initiated by international non-governmental-organization PATH and Indian Council of Medical Research for GSK and Merck vaccines respectively, were called off early this year after six deaths were reported among the girls who were administered these vaccines in Gujarat and Andhra Pradesh.
The world's second-largest drug maker, GlaxoSmithKline (GSK), is making India a major manufacturing hub for its free global drug supply to treat neglected diseases.
In the international market, Pfizer completed its acquisition of Wyeth in 2009.
With the expectation of a big rise in the market for 'sensitive toothpastes' in the near term, GlaxoSmithKline (GSK), the largest company in the health food sector, has forayed into this category in India with its biggest global brand, Sensodyne Toothpaste. This has been launched across all metropolitan and Tier-I cities.
Glenmark Generics Inc has settled the litigation pending between the company and GSK over patent actions concerning atovaquone and proguanil hydrochloride 250mg/100mg tablets, the generic version of GSK's Malarone tablets, Glenmark Pharma said.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.
GlaxoSmithKline, the world's second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value.
Hindustan Unilever Ltd, India's largest personal care product maker, on Tuesday reported a better-than-expected increase in its September quarter net profit and revenues, signalling a revival of demand following the world's biggest lockdown.
GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies.
In a good news for those who find it hard to kick the butt, a new vaccine which would help them quit smoking would soon be available in the market.
US-based Merck is confident that its cervical cancer vaccine Gardasil will help it to secure a position among the country's top five drug companies in the next five years.
Ranbaxy has six-month exclusive marketing right to anti-herpes Valtrex.
Mahindra Satyam on Thursday said it has signed a five-year multi-million dollar deal with UK-based GlaxoSmithKline to provide SAP and other critical systems support.Satyam has been working with GSK since 2002 in providing IT application development and support services, Mahindra Satyam said in a statement.
Dr Reddy's has reached an out-of-court settlement to launch the Glaxo-patented Imitrex, a migraine drug that had annual sales of $878 million as of March 31, 2006, in the US. Experts estimate Dr Reddy's may not get more than $8-$15 million sales in 2009 since majority of sales revenue has to be given to GSK, for allowing the launch the authorised generic version.
GSK India, which has a turnover of Rs 1,751 crore (Rs 17.51 billion) and launched a cervical cancer drug, Cervarix, and breast cancer drug, Tykerb, last year, plans to launch Promacta, the first oral medication to increase platelet production for people with serious blood disorder, from its parent stable during the current year. Promacta is a relatively new drug, for which approval was given by the US Food and Drug Administration in November last year.
Pharmaceutical giant GlaxoSmithKline has slashed prices of drugs for the poorest countries and is sharing part of the profits with these countries to beef up health facilities. CEO Andrew Witty said, ' We have the capacity to do more and we can do more. The question is can we, big pharmaceutical companies, rise to the challenge and be a genuine catalyst for change?'
GlaxoSmithKline Consumer Healthcare is leveraging on Horlicks' brand equity to get into new categories. Will the move pay off?
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances